Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of RSVpreF Vaccine in High-Risk Adults in Japan
jRCT2031260083Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- May 2026
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of RSVpreF vaccine in respiratory syncytial virus disease (RSV), sponsored by Pfizer. Primary endpoints: Prompted local reactions within 7 days, Prompted systemic events within 7 days and 3 more. Started May 2026; status: active, not recruiting.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2031260083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260083.